Target Corp (TGT) stock plunged 7% after missing earnings estimate in the third quarter. Net income rose 20% to $1.09 cents per share, lower than the average analysts’ estimate of $1.11 per share. Higher investments to improve supply chain efficiency hurt Target’s margins during the quarter.
On a GAAP basis, net income rose to $1.17 per share, compared to $0.87 per share during the same period last year.
The company reported 5.1% growth in comp sales driven by healthy increases in both store and digital channels. However, this came slightly below the Street consensus of 5.2%. Thanks to the increasing investments in the digital platform, comparable online sales jumped 49% in Q3.
Revenue of the department store chain rose 5.6% to $17.8 billion. Analysts had expected revenue of $17.75 billion during the quarter.
Target CEO Brian Cornell said, “We’ve made significant investments in our team heading into the holidays and they are ready to serve our guests with a comprehensive suite of convenient delivery and pickup options, a wide range of new products and unique gift ideas and a strong emphasis on low prices and great value.”
Why Target is a better investment than Walmart this holiday season
Despite the earnings miss, Target remains optimistic about the holiday quarter, when it anticipates comp sales growth of about 5%. The company also reiterated its guidance for full-year adjusted EPS between $5.30 and $5.50.
Target shares have increased 15% so far this year.
During the prior-sequential quarter (Q2), a 6.4% jump in store traffic had driven Target’s top line higher by 7%. Earnings grew 19% riding on the sales growth and lower income taxes. The results had also benefited from various merchandising strategies including cost-savings initiatives and efforts to improve pricing and promotions.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on